Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody

Inclusion Criteria

• •Male or female
• •≥ 18 years of age at the time of signing the informed consent document
• •Clinical diagnosis of BP confirmed by histology, immunohistochemistry and/or ELISA data
• •Patient requiring a treatment by superpotent topical steroids
• •Patients hospitalized for the treatment of their BP
• •For female, only post-menopaused patients
• •For male patients included in the study with partners of child bearing potential should agree to use highly effective contraception for the duration of the study and 6 months after the last dose of avdoralimab
• •Signed informed consent document prior to any study related assessments/procedures being conducted
• •Patient able to adhere to the study visit schedule and other protocol requirements
• •Patient registered to the French Social Security